Grann Pharma’s Vision

Our pipeline applies Grann’s mRNA lipid nanoparticle platform across rare genetic disorders, oncology, and metabolic disease. We are advancing investigational programs at different stages of research and development, with RTT-1 for Rett syndrome as our lead program.

Grann Pharma’s Approach


A woman holding a young girl with a bandaged head and face, both touching foreheads and smiling at each other in a bright indoor space.

RTT-1 is an investigational mRNA lipid nanoparticle therapeutic designed to support MECP2 protein expression. Two girls have received RTT-1 through single-patient expanded access, with third-patient dosing upcoming and Phase 1 development planned.

Clinical monitoring, laboratory assessments, and caregiver observations are informing continued development. These individual observations do not establish safety or efficacy.

Development & Access

Grann is advancing multiple investigational programs through research and development. Patients, families, and treating physicians may contact our team about a specific program or another disease of interest. We review inquiries in the context of our scientific approach, available evidence, and development capabilities. Submitting an inquiry does not guarantee that Grann can develop a therapy, initiate a study, or provide treatment.

Two girls have received RTT-1 through single-patient expanded access. Grann is preparing for further clinical development, including a planned Phase 1 study. Families and treating physicians may contact our team to ask about the program’s current status and potential future opportunities. Submitting an inquiry does not guarantee eligibility, participation, or access to treatment.

About Expanded Access

Expanded access is a potential pathway for eligible patients with serious or life-threatening conditions to receive an investigational treatment outside a clinical trial when no comparable or satisfactory alternative therapy is available. Access requires medical review, company agreement, and applicable regulatory and ethics approvals.

Blood-Brain Barrier

Grann Pharmaceuticals Inc. has put forth continued research efforts into developing a lipid nanoparticle delivery system capable of crossing the Blood Brain Barrier (BBB). Current research indicates that any particle < 100 nm - 150 nm has the capability to cross the BBB (Nance et al., 2012).

​

​

Here at Grann Pharmaceuticals, we have tailored our lipid nanoparticles to an average size of 80 nm to successfully deliver mRNA and small molecules across the BBB. This has been observed in multiple animal trials spanning across several different species of mice.

​​Our goal at Grann Pharmaceuticals is to apply this lipid nanoparticle technology in therapeutics for CNS disorders and neurological diseases such as Obesity, Rett Syndrome, GABA-A Variants, Alzheimer’s and cancer.

Illustration of a blood vessel with labels pointing to endothelial cell, blood, extracellular vesicles, pericyte, and astrocyte, depicting a biological process.